PRIVIGEN SOLUTION FOR INFUSION 100G/L

CSL BEHRING AG (SWITZERLAND)🇸🇬 Health Sciences Authority

Approval Date: Nov 7, 2018
Approval ID: c6040ce93a0feadf
Company: CSL BEHRING AG (SWITZERLAND)
Type: Therapeutic

Approval Details

Approval Id: c6040ce93a0feadf
Drug Name: PRIVIGEN SOLUTION FOR INFUSION 100G/L
Product Name: PRIVIGEN SOLUTION FOR INFUSION 100G/L
Approval Number: SIN15574P
Approval Date: 2018-11-07
Registrant: CSL BEHRING PTE. LTD.
Licence Holder: CSL BEHRING PTE. LTD.
Drug Type: Therapeutic
Forensic Classification: PRESCRIPTION ONLY MEDICINES
Dosage Form: INFUSION, SOLUTION
Dosage: 4.2 Posology and method of administration Replacement therapy should be commenced and monitored under the supervision of a physician experienced in the treatment of immunodeficiency. Posology The dose and dose regimen is dependent on the indication. In replacement therapy the dose may need to be individualised for each patient depending on the clinical response. Dose based on bodyweight may require adjustment in underweight or overweight patients. The following dose regimens are given as a guideline. Replacement therapy in primary immunodeficiency (PID) syndromes The dose regimen should achieve a trough IgG level (measured before the next infusion) of at least 6 g/l or within the normal reference range for the population age. Three to six months are required after the initiation of therapy for equilibration to occur. The recommended starting dose is 0.4 to 0.8 g/kg body weight (bw) given once, followed by at least 0.2 g/kg bw every 3 to 4 weeks. The dose required to achieve a trough level of IgG of6 g/l is of the order of 0.2 to 0.8 g/kg bw/month. The dosage interval when steady state has been reached varies from 3 to 4 weeks. IgG trough levels should be measured and assessed in conjunction with the incidence of infection. To reduce the rate of bacterial infections, it may be necessary to increase the dosage and aim for higher trough levels. Secondary immunodeficiencies (as defined in 4.1) The dose regimen should achieve a trough IgG level (measured before the next infusion) of at least 6 g/l or within the normal reference range for the population age. The recommended dose is 0.2 – 0.4 g/kg every three to four weeks. IgG trough levels should be measured and assessed in conjunction with the incidence of infection. Dose should be adjusted as necessary to achieve optimal protection against infections, an increase may be necessary in patients with persisting infection; a dose decrease can be considered when the patient remains infection free. Primary immune thrombocytopenia (ITP) There are two alternative treatment schedules: <ul> <li>0.8 to 1g/kg bw given on day 1; this dose may be repeated once within 3 days</li> <li>0.4 g/kg bw given daily for 2 to 5 days.</li> </ul> The treatment can be repeated if relapse occurs. Guillain-Barré syndrome 0.4 g/kg bw/day over 5 days (possible repeat of dosing in case of relapse). Kawasaki disease 2.0 g/kg bw should be administered as a single dose. Patients should receive concomitant treatment with acetylsalicylic acid. Chronic inflammatory demyelinating polyneuropathy (CIDP)* The recommended starting dose is 2 g/kg bw divided over 2 to 5 consecutive days followed by maintenance doses of 1 g/kg bw over 1 to 2 consecutive days every 3 weeks. The treatment effect should be evaluated after each cycle; if no treatment effect is seen after 6 months, the treatment should be discontinued. If the treatment is effective long term treatment should be subject to the physicians discretion based upon the patient response and maintenance response. The dosing and intervals may have to be adapted according to the individual course of the disease. Multifocal Motor Neuropathy (MMN) Starting dose: 2 g/kg given over 2–5 consecutive days. Maintenance dose: 1 g/kg every 2 to 4 weeks or 2 g/kg every 4 to 8 weeks. The treatment effect should be evaluated after each cycle. If insufficient treatment effect is seen after 6 months, the treatment should be discontinued. If the treatment is effective, long term treatment should be subject to the physician’s discretion based upon the patient response. The dosing and intervals may have to be adapted according to the individual course of the disease. The dosage recommendations are summarised in the following table: <img src="/TGIF/Privigen-Table1_300822.png" alt="Privigen Dosage Table 1" /> Paediatric population The posology in children and adolescents (0–18 years) is not different from that of adults as the posology for each indication is given by body weight and adjusted to the clinical outcome of the above mentioned conditions. Hepatic impairment No evidence is available to require a dose adjustment. Renal impairment No dose adjustment unless clinically warranted, see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. Elderly No dose adjustment unless clinically warranted, see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information. Method of administration For intravenous use. Privigen should be infused intravenously at an initial infusion rate of 0.3 ml/kg bw/hr for approximately 30 min. If well tolerated (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information), the rate of administration may gradually be increased to 4.8 ml/kg bw/hr. In PID patients who have tolerated the infusion rate of 4.8 ml/kg bw/hr well, the rate may be further increased gradually to a maximum of 7.2 ml/kg bw/hr. If dilution prior to infusion is desired, Privigen may be diluted with 5% glucose solution to a final concentration of 50 mg/ml (5%). For instruction, see section 6.6 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.
Route Of Administration: INTRAVENOUS
Indication Info: 4.1 Therapeutic indications Replacement therapy in adults, and children and adolescents (0–18 years) in: <ul class="dash"> <li>Primary immunodeficiency (PID) syndromes with impaired antibody production (see section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).</li> <li>Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of <4 g/l.</li> </ul> * PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines. Immunomodulation in adults, and children and adolescents (0–18 years) in: <ul class="dash"> <li>Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count.</li> <li>Guillain-Barré syndrome.</li> <li>Kawasaki disease. (in conjunction with acetylsalicylic acid; see section 4.2.).</li> <li>Chronic inflammatory demyelinating polyneuropathy (CIDP). Only limited experience is available of use of intravenous immunoglobulins in children with CIDP.</li> <li>Multifocal motor neuropathy (MMN)</li> </ul>
Contraindications: 4.3 Contraindications Hypersensitivity to the active substance (human immunoglobulins) or to any of the excipients listed in section 6.1 (see also section 4.4 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). Patients with selective IgA deficiency who developed antibodies to IgA, as administering an IgA-containing product can result in anaphylaxis.Patients with hyperprolinaemia type I or II.
Atc Code: J06BA02
Atc Item Name: immunoglobulins, normal human, for intravascular adm.
Pharma Manufacturer Name: CSL BEHRING PTE. LTD.

Active Ingredients

Human Immunoglobulin

100g/L

Human Immunoglobulin

100g/L

Approved

Quick Info

Agency

HSA

Country

🇸🇬

Approval Date

Nov 7, 2018

Approval ID

c6040ce93a0feadf

Type

Therapeutic

Back to HSA Approvals